anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Obesity is associated with increased morbidity and mortality during bacterial pneumonia. Cyclooxygenase-2 (COX-2) and PGE2 have been shown to be upregulated in patients who are obese. In this study, we investigated the role of obesity and PGE2 in bacterial pneumonia and how inhibition of PGE2 improves antibacterial functions of macrophages. C57BL/6J male and female mice were fed either a normal diet (ND) or high-fat diet (HFD) for 16 wk. After this time, animals were infected with Pseudomonas aeruginosa in the lung. In uninfected animals, alveolar macrophages were extracted for either RNA analysis or to be cultured ex vivo for functional analysis. HFD resulted in changes in immune cell numbers in both noninfected and infected animals. HFD animals had increased bacterial burden compared with ND animals; however, male HFD animals had higher bacterial burden compared with HFD females. Alveolar macrophages from HFD males had decreased ability to phagocytize and kill bacteria and were shown to have increased cyclooxygenase-2 and PGE2. Treating male, but not female, alveolar macrophages with PGE2 leads to increases in cAMP and decreased bacterial phagocytosis. Treatment with lumiracoxib-conjugated nanocarriers targeting alveolar macrophages improves bacterial phagocytosis and clearance in both ND and HFD male animals. Our study highlights that obesity leads to worse morbidity during bacterial pneumonia in male mice because of elevated PGE2. In addition, we uncover a sex difference in both obesity and infection, because females produce high basal PGE2 but because of a failure to signal via cAMP do not display impaired phagocytosis.
Medical cannabis" encompasses the use of cannabis and cannabinoids for therapeutic purposes. Includes drugs approved by regulatory agencies and pharmaceutical products. Recently, many countries have authorized the use of cannabis flower cups with a standardized amount of Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD) and their acidic precursors (Δ-9-tetrahydrocannabinolic acid A \[THCA\] and cannabidiol acid \[ CBDA\]) for the treatment of different diseases. In Italy since January 2017 there has been for sale a standardized cannabis preparation produced by the Military Pharmaceutical Institute of Florence. This medicinal variety of cannabis sativa, known as FM2 has a variable THC and CBD percentage of between 5-8% and 7-12% respectively. To date, there are no studies on the pharmacokinetics of THC, CBD and other minor cannabinoids in conventional and unconventional biological matrices after oral administration of cannabis tea, cannabis oil and vaporized with the same medicinal preparation (FM2). The main objective is to know the concentrations of THC, CBD and metabolites, and other cannabinoids in blood, urine, oral fluid and sweat after the experimental administration of a standardized cannabis preparation orally (two formulations: cannabis tea and cannabis oil) and vaporized. In addition, the acute pharmacological effects and tolerability will be evaluated. Healthy recreational cannabis users with experience in oral use of cannabis will participate
The subjects enrolled in the invention group will be shown a 5 minute educational video on hypertension in the postpartum period. The patients will be shown the video on the ipad while they are in the comfort of their room. They will also be provided with a pamphlet with similar information that was discussed in the video. They will also be asked to complete a brief, anonymous survey to assess patient satisfaction with the video shown, no patient identifiers will be collected.
Ventricular aneurysm represents a rare complication of transmural acute myocardial infarction, although other cardiac, congenital, or metabolic diseases may also predispose to such condition. Ventricular expansion includes all the cardiac layers, usually with a large segment involved. Adverse events include recurrent angina, reduced ventricular stroke volume with congestive heart failure, mitral regurgitation, thromboembolism, and ventricular arrhythmias. Multimodality imaging is paramount to provide comprehensive assessment, allowing for appropriate therapeutic decision-making. When indicated, surgical intervention remains the gold standard, although additional therapy (heart failure, anticoagulation, and advanced antiarrhythmic treatment) might be required. However, the STICH (Surgical Treatment for Ischemic Heart Failure) trial did not show any advantage from adding surgical ventricular reconstruction to coronary artery bypass surgery in terms of survival, rehospitalization or symptoms, compared with revascularization alone. Finally, implantable cardiac defibrillator may reduce the risk of fatal arrhythmias.
OBJECTIVES: The purpose of the study is to examine the outcomes of care delivered at the pediatric trauma center (PTC) in severely injured children who were intubated, mechanically ventilated, and underwent tracheostomy.
METHODS: The study data were obtained from the Trauma Quality Improvement Program database for the calendar years 2017 to 2019. All children aged ≤17 years who sustained severe injury, required intubation and mechanical ventilation for more than 96 hours, and underwent tracheostomy were included in the study. Patients' characteristics, injury severity, and outcomes were compared between the care provided at the PTCs (level I or level II) and nonpediatric trauma centers (NPTCs). The propensity score matching methodology was used to perform the analysis. All P values are 2-sided, and a P value of <0.0.5 is considered statistically significant.
RESULTS: Of 2164 patients who were qualified for the study, 1288 (59%) of the patients were treated at PTCs, and 876 (40.5%) of the patients were treated at NPTCs. Propensity matching created 876 pairs of patients. There were no significant differences found between the 2 groups on patients' characteristics except for age. Patients who were treated at PTCs had a median age of 14 (10-16) versus 15 (11-17) years ( P < 0.001) when compared with care provided at NPTCs. A longer hospital stay was found in the PTC group when compared with the NPTC group (24 [23, 25] vs 22 [21, 24], P = 0.008). Patients who were treated at PTC were found to have significantly less sepsis occurrence (0.9% vs 2.2%), and a higher proportion of patients were discharged home without needing additional support (26.2% vs 18.5%).
CONCLUSIONS: Care at the PTC was associated with a lower occurrence of sepsis complications. A higher number of patients were discharged home without additional services when the care was provided at PTC.
An operation and the constant further development of the surgical techniques can not always prevent the recurrence of a tumor of the stomach or the transition from the esophagus to the stomach. As reason for this recurrence, the investigators assume that the tumor was already present at the time of the surgery and has crossed the boundaries of the stomach or free tumor cells are located in the peritoneal cavity, even if they can't be found with the bare eye or imaging methods. Such free tumor cells have the possibility of developing metastases within the abdominal cavity.

An innovative local treatment method is being tested in Tübingen and applied to remove any remaining free tumor cells or very small and invisible residual tumors. These free tumor cells can be determined prior to the start of treatment by peritoneal endoscopy (diagnostic laparoscopy). If these can be identified by lavage of the abdominal cavity there is an increased risk for the development of peritoneal metastases. Therefore, in patients with detected free tumor cells in the lavage water of the abdominal cavity, after the removal of the stomach, should be used once a chemotherapy in the abdominal cavity, which is warmer than the body (intraoperative hyperthermic chemotherapy, HIPEC). In this study the investigators want to demonstrate, that the single administration of intraoperative HIPEC with cisplatin and doxorubicin in addition to routine surgery delays the onset of peritoneal metastases and the additional therapy with its low risks is reasonable.
The invention relates to a novel zinc complex of gamma-L-glutamyl histamine with a metal/ligand ratio of 1/1. In particular, the invention relates to a compound of formula (I). The complex according to the invention promotes the recovery of barrier functions of epithelial tissue and suppresses aberrant activity of immune system cells. The invention also relates to the production of the complex and the use of said zinc complex for the treatment of atopic dermatitis and other diseases associated with the disruption of barrier functions of epithelial tissue and the development of an aberrant inflammatory response. The invention also relates to the use of the obtained complex for inhibiting glutaminyl cyclase. The present invention also relates to pharmaceutical compositions containing a therapeutically effective quantity of the compound according to the invention.
PURPOSE:To automatize the job of a pharmacist by extracting the attribute data of a patient in a patient master corresponding to inputted prescription data and the attribute data of a medicine in a medicine master, respectively, and finding the optimum medicine combining data by developing extracted patient data and medicine data based on a medicine combination rule. CONSTITUTION:An operator (pharmacist) inputs the prescription data of a prescription such as a patient number and a prescription content, etc., issued by a doctor from a keyboard comprising a prescription data input part 1 as observing a CRT display 6. Inputted prescription data is fetched in a chack part 9 via an input part 8, and respective check processing is executed. When all the check processings are completed, a check list is outputted from a printer 7 via an output part 11. Also, checked medicine combining data is outputted to the patient master 2, and corresponding patient data is rewritten. On the check list, the bibliographical items of the patient number, a name, distinction of sex, the date of birth, and the name of a disease, etc., and the code of the medicine to be applied, the name of a prescribed medicine, and a check content (instructing way to take medicine) are entered. In such a way, it is possible to automatize the complicated job of the pharmacist and to reduce the labor of the job.
Sleep deficiency is a rampant issue in modern society, serving as a pathogenic element contributing to learning and memory impairment, with heightened sensitivity observed in children. Clinical observations suggest that learning disabilities associated with insufficient sleep during adolescence can persist through adulthood, but experimental evidence for this is lacking. In this study, we examined the impact of early-life sleep deprivation (SD) on both short-term and long-term memory, tracking the effects sequentially into adulthood. We employed a modified multiple-platform method mouse model to investigate these outcomes. SD induced over a 14-day period, beginning on postnatal day 28 (PND28) in mice, led to significant impairment in long-term memory (while short-term memory remained unaffected) at PND42. Notably, this dysfunction persisted into adulthood at PND85. The specific impairment observed in long-term memory was elucidated through histopathological alterations in hippocampal neurogenesis, as evidenced by bromodeoxyuridine (BrdU) signals, observed both at PND42 and PND85. Furthermore, the hippocampal region exhibited significantly diminished protein expressions of astrocytes, characterized by lowered levels of aquaporin 4 (AQP4), a representative molecule involved in brain clearance processes, and reduced protein expressions of brain-derived neurotrophic factors. In conclusion, we have presented experimental evidence indicating that sleep deficiency-related impairment of long-term memory in adolescence can endure into adulthood. The corresponding mechanisms may indicate that the modification of astrocyte-related molecules has led to changes in hippocampal neurogenesis.
In the past decade, frailty has attracted great attention of the scientific community and public health organizations as precursor and contributor of age-related diseases. Frailty is a common clinical syndrome in older adults, affecting 7-12% of the older population, and the occurrence of frailty increases with age and may exceed 45% after age 85 years. Frailty develops when age-associated degenerative processes overwhelm reserve capacity and reparative processes that maintain function of the nervous system as well as other physiologic systems. Overall, frailty consists in the vulnerability of aged population to adverse events as the result of the subtle and progressive metabolic and physical changes. Frailty confers a significantly increased risk for poor health outcomes, incident disability, hospitalization, and mortality.

In recent years there has been an emergence of information and communication technology (ICT) -based solutions to support active ageing and tackle frailty, cognitive decline and social isolation of older adults. While these ICT-based solutions are of a certain value regarding diminishing single risks (e.g. fall risk, etc.), there is still a need for a more holistic approach which aims to address all of the individual risk factors together. Also it is necessary to provide tailored interventions based on the outcomes of the risk analysis. This assessment of risk for frailty and provision of individual tailored interventions is the main objective of My-AHA project.

My-AHA solution supports active and healthy ageing by enabling early detection and minimization of risks associated with ageing. In these terms the early risk detection considers three fundamental aspects of the life of older adults: physical activity (by considering vital signs data, gait, quality of sleep and in general, physical activity, and fall risk); cognitive activity (by monitor the cognitive level, e.ge.g. in cognitive games); and, psychosocial activities (e.g. by analyzing the emotions and the quality of speech of the users). On the other hand, My-AHA will develop and implement more efficient and effective ICT-based interventions tailored to the early identified risks. The suggested social activities, as well as cognitive and physical trainings and the diet proposed to the older adults via the new platform will help the users in changing their behaviour and in reacting to the consequences of ageing.
The invention discloses an application of anemonin B4 derivative A3-9 in preparing a medicament for preventing and treating inflammatory bowel disease. The existing chemical drugs have toxic and side effects, and the drug properties of the Chinese herbal medicine extracts need to be improved. The medicine A3-9 provided by the invention has obvious therapeutic effect on colonitis, and the result shows that the high dose A3-9 can be used for lavaging the stomach, has no structural damage to the body weight and organs of mice, and has better safety while effectively relieving and treating colonitis. The A3-9 has the advantages of obvious curative effect on inflammatory bowel disease, low toxic and side effect and high safety, is expected to be used for clinical treatment of inflammatory bowel disease, and solves the problems of insufficient curative effect, more side effect and high toxicity of the traditional medicine. In addition, the A3-9 can improve the survival rate of animals which are dead to the colonitis, and the curative effect is better than that of positive control medicine mesalamine. Therefore, anemonin B4 derivatives A3-9 can treat or prevent inflammatory bowel disease.
An apparatus is disclosed that allows for the delivery of medications and or chemicals for treatment of tissue through permeable dermal patch positioned inside a vessel for use in treating of any particular disease or aliment. The vessel self-adheres through activation of a chemical heater which may be activated by a pull tab exterior of the vessel. Initiation of the chemical reaction generates heat sufficient to raise the air temperature inside the vessel to allow the vessel to auto-generate a vacuum for wound treatment and to aid in sterilization of the wound site. The heated air expands and is evacuates through a one-way valve exterior of the vessel. Cooling of the interior air generates a vacuum inside the vessel to create a suction that holds the vessel in place. Increases blood flow to the treated tissue area, stimulated by the vacuum, facilitates improved delivery of the medication or pharmacological composition to the user. Application of vacuum to the treated tissue disinfects the tissue while providing a bacterial infiltration barrier.
This is an open-label, multicenter, global study to evaluate the contraceptive efficacy, cycle control, safety, compliance and subject satisfaction of the transdermal contraceptive system. Sixteen hundred healthy women will wear the contraceptive patch for either 6 or 13 cycles. The first 530 subjects will wear the patch for 13 cycles, and all subsequent subjects will wear the patch for 6 cycles. At admission Visit 1, study drug (plus 3 reserve patches) and diary cards are dispensed for Cycle 1; first patch application will be on the first day of menses. Study drug and diary cards are dispensed on day 28 of Cycle 1 (Visit 2) for Cycles 2 and 3, on day 28 of Cycle 3 (Visit 3) for Cycles 4 to 6, on day 28 of Cycle 6 (Visit 4) for Cycles 7 to 9, and on day 28 of Cycle 9 (Visit 5) for Cycles10 to13. At each of these visits, diary cards and empty medication packages are collected. Final study visits are on day 28 of Cycles 6 and 13. Diary card information is used to record compliance and bleeding information (to assess cycle control). Contraceptive efficacy is assessed by means of the Pearl Index and life table analysis (gross cumulative probability of pregnancy). Safety evaluations are based on adverse events, which are collected throughout the study, and changes in gynecologic examinations, vital signs, and laboratory results from admission to final visit. Each transdermal contraceptive patch, containing 6 mg NGM and 0.75 mg EE, and delivering 250 ug 17-dNGM and 25 ug EE over 24 hours for 7 days, is worn for 1 week and replaced for 3 consecutive weeks. The fourth week is patch-free. The patch can be worn on: upper arm or torso, buttock, or abdomen.
PROBLEM TO BE SOLVED: To provide an easily useable stick cosmetic with which 2 color cosmetic, light and shade, may be easily applied on skin while making gradation.SOLUTION: A stick cosmetic 10 comprises cosmetics A, B having 2 colors of light and shade integrally combined via a boundary surface 15 extending along its longitudinal direction. A transverse section thereof has an outline where the size in width direction is larger than the size in forth and back direction. The stick cosmetic 10 may be divided into 3 regions with 2 virtual lines Y, Yvertical to a virtual line X crossing the transverse section in forth and back direction. A first region positioned at one end side is constructed with only a section of shade color cosmetic A. A second region positioned at middle area is constructed with a section of the shade color cosmetic A and a section of light color cosmetic B. A third region positioned at the other end side is constructed with only a section of the section of light color cosmetic B.
A thin film (10) or layer (10) of white blood cells, such as the contaminating white cells in a platelet concentrate, is irradiated with ultraviolet radiation predominantely of a wavelength of 280 to 320 nanometers, and preferably at an intensity of 4 to 20 milliwatts per square cm. to provide a total energy exposure of typically 800 to 20,000 millijoules per square cm. of ultraviolet radiation. The white blood cells so processed substantially lose their capability to set off an immune reaction in an alloimmunized patient. The white blood cells may preferably be placed into such film in a flat (10), flexible bag (10) made of poly(ethylene-vinyl acetate) plastic, with the flat (10), flexible bag (10) being stretched in a direction normal to the path of ultraviolet radiation. Novel irradiating devices (40) are also disclosed.
Based on published reports and its mechanism of action, methotrexate can cause embryo-fetal toxicity, including fetal death when administered to a pregnant woman.

Methotrexate Injection is contraindicated for use in pregnant women with non-neoplastic diseases. Advise pregnant women with neoplastic diseases of the potential risk to a fetus. The preservative benzyl alcohol can cross the placenta; when possible, use the preservative-free formulation when Methotrexate Injection is needed during pregnancy to treat a neoplastic disease [see Warnings and Precautions (5.3)].

Advise females of reproductive potential to use effective contraception during Methotrexate Injection treatment and for 6 months after the final dose. Advise males with female partners of reproductive potential to use effective contraception during Methotrexate Injection treatment and for 3 months after the final dose [see Contraindications (4) and Use in Specific Populations (8.1, 8.3, 8.4)].
A solidifying implant composition of a polymer mixed with a bioabsorbable solvent. A method of treating a patient, by implanting the solidifying implant composition into bone, and solidifying the implant composition. A method of improving bone structure in patients by applying the solidifying implant composition to bone, shoring up bone structure, and improving load bearing capacity and aiding healing of microfractures.. A method of fixing an implant, by applying the solidifying implant composition to an implant, and shoring up the implant. A method of devascularizing and treating a tumor or vascular lesion. A method of treating a vascular disease. A method of treating aneurysms/pseudoaneurysms.
The present application relates to the molecular labeling and in vivo imaging of amyloids. Specifically, the present application relates to a polypeptide-based method/vector for targeting amyloids. Such a method/vector enables the transportation of compounds or drugs across blood-brain-barrier of an individual and then binding to amyloids in brain. Particularly, the vector of the present application can transport an imaging group linked to the vector across the blood-brain-barrier, and can binds to amyloids in brain, and thus enables the labeling and imaging of amyloid deposits. When used as an imaging agent for detecting amyloid deposits in body or tissues, the vector may be labeled with suitable optical imaging groups, radioactive isotopes or imaging groups suitable for MRI or CT detection. The method/vector can especially used for the in vivo non-invasive diagnosis of amyloid-related diseases including Alzheimer's disease, and for the observation of the therapeutic effect of drugs targeting amyloid deposits.